Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery

World Neurosurgery

Volumn 98, Issue , 2017, Pages 525-531

  Zhang, Yuyi ^a,b   Zhang, Jing ^a,c   Chen, Yuancheng ^a,c   Yu, Jicheng ^a,c   Cao, Guoying ^a,c   Wu, Xiaojie ^a,c   Chen, Mingyu ^a   Wu, Jufang ^a,c   Zhao, Xu ^a,c  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Cerebrospinal fluid; Meropenem; Nosocomial infection; Penetration; Postneurosurgical meningitis

Indexed keywords

DOXYCYCLINE; LEVOFLOXACIN; MEROPENEM; VANCOMYCIN; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ACINETOBACTER INFECTION; ADULT; AGED; ARTICLE; BACTERIAL MENINGITIS; BLOOD SAMPLING; BRAIN HERNIA; CEREBROSPINAL FLUID; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG INFUSION; DRUG PENETRATION; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; OPEN STUDY; PROSPECTIVE STUDY; RASH; TREATMENT RESPONSE; ULTRAVIOLET SPECTROSCOPY; ADVERSE EFFECTS; AREA UNDER THE CURVE; BLOOD; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MENINGITIS, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUROSURGICAL PROCEDURES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME;

EID: 85006391379     PISSN: 18788750     EISSN: 18788769     Source Type: Journal    
DOI: 10.1016/j.wneu.2016.11.040     Document Type: Article

References (29)

1. 1 National Nosocomial Infections Surveillance System, National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32 (2004), 470–485.
2. 2 Sharma, M.S., Vohra, A., Thomas, P., Kapil, A., Suri, A., Chandra, P.S., et al. Effect of risk-stratified, protocol-based perioperative chemoprophylaxis on nosocomial infection rates in a series of 31 927 consecutive neurosurgical procedures (1994-2006). Neurosurgery 64 (2009), 1123–1130.
3. 3 van de Beek, D., Drake, J.M., Tunkel, A.R., Nosocomial bacterial meningitis. N Engl J Med 362 (2010), 146–154.
4. 4 McClelland, S. 3rd, Hall, W.A., Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures. Clin Infect Dis 45 (2007), 55–59.
5. 5 Ramos-Martínez, A., de Las Heras-Carballo, T., Fernández-Mateos, C., de Reina, L., Alvarez de Espejo-Montiel, T., Escamilla-Fernández, N., et al. Postsurgical meningitis. Differential characteristics of aseptic postsurgical meningitis. Neurocirugia (Astur) 20 (2009), 103–109.
6. 6 Malekpour-Afshar, R., Karamoozian, S., Shafei, H., Post traumatic meningitis in neurosurgery department. Am J Infect Dis 5 (2009), 21–25.
7. 7 Kempf, M., Rolain, J.M., Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 39 (2012), 105–114.
8. 8 Chen, M.Y., Zhong, P., Wu, J.F., Xu, J., Xu, M., Chen, D.Q., et al. Clinical analysis of 45 cases of intracranial infection after neurosurgery. Chin J Infect Chemother 12 (2012), 365–367.
9. 9 Tunkel, A.R., Hartman, B.J., Kaplan, S.L., Kaufman, B.A., Roos, K.L., Scheld, W.M., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 (2004), 1267–1284.
10. 10 Chaudhuri, A., Martinez-Martin, P., Kennedy, P.G., Andrew Seaton, R., Portegies, P., Bojar, M., et al., EFNS Task Force. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol 15 (2008), 649–659.
11. 11 Lodise, T.P., Nau, R., Kinzig, M., Drusano, G.L., Jones, R.N., Sörgel, F., Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother 60 (2007), 1038–1044.
12. 12 Morita, A., Kamei, S., Minami, M., Yoshida, K., Kawabata, S., Kuroda, H., et al. Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan. J Infect Chemother 20 (2014), 535–540.
13. 13 Tsumura, R., Ikawa, K., Morikawa, N., Ikeda, K., Shibukawa, M., Iida, K., et al. The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients. J Chemother 20 (2008), 615–621.
14. 14 Zhang, Y.Y., Yu, J.C., Lin, D.F., Xu, X.G., Zhang, J., Wu, J.F., Determination of meropenem in human cerebrospinal fluid by HPLC. Chin J Clin Pharm 20 (2011), 28–30.
15. 15 Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement M100-S24. 2014, CLSI, Wayne, PA.
16. 16 Fink, M., Letellier, I., Peyrou, M., Mochel, J.P., Jung, M., King, J.N., et al. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis. Res Vet Sci 95 (2013), 580–587.
17. 17 Beal, S.L., Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28 (2001), 481–504.
18. 18 Chen, Y., Cao, Y., Zhou, J., Liu, X., Mechanism-based pharmacokinetic–pharmacodynamic modeling of bidirectional effect of danshensu on plasma homocysteine in rats. Pharm Res 26 (2009), 1863–1873.
19. 19 Cascio, A., Conti, A., Sinardi, L., Iaria, C., Angileri, F.F., Stassi, G., Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis 14 (2010), e572–e579.
20. 20 Kim, B.N., Peleg, A.Y., Lodise, T.P., Lipman, J., Li, J., Nation, R., et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis 9 (2009), 245–255.
21. 21 Khan, F.Y., Abukhattab, M., Baager, K., Nosocomial postneurosurgical Acinetobacter baumannii meningitis: a retrospective study of six cases admitted to Hamad General Hospital, Qatar. J Hosp Infect 80 (2012), 176–179.
22. 22 Tuon, F.F., Penteado-Filho, S.R., Amarante, D., Andrade, M.A., Borba, L.A., Mortality rate in patients with nosocomial Acinetobacter meningitis from a Brazilian hospital. Braz J Infect Dis 14 (2010), 437–440.
23. 23 Metan, G., Alp, E., Aygen, B., Sumerkan, B., Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J Antimicrob Chemother 60 (2007), 197–199.
24. 24 Moon, Y.S., Chung, K.C., Gill, M.A., Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis 24:suppl 2 (1997), S249–S255.
25. 25 Bax, R.P., Bastain, W., Featherstone, A., Wilkinson, D.M., Hutchison, M., Haworth, S.J., The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 24:suppl A (1989), 311–320.
26. 26 Dandekar, P.K., Maglio, D., Sutherland, C.A., Nightingale, C.H., Nicolau, D.P., Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 23 (2003), 988–991.
27. 27 Ikawa K, Tsumura R, Morikawa N, Ikeda K, Shibukawa M, Iida K, et al. Cerebrospinal fluid penetration and pharmacodynamic exposure of meropenem prophylactically administered to neurosurgical patients. Paper presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases. April 19-22, 2008; Barcelona, Spain.
28. 28 Nau, R., Lassek, C., Kinzig-Schippers, M., Thiel, A., Prange, H.W., Sörgel, F., Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother 42 (1998), 2012–2016.
29. 29 Lutsar, I., McCracken, G.H. Jr., Friedland, I.R., Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 27 (1998), 1117–1127.